Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
CanadaIPO:
29 October 2019Website:
http://www.profoundmedical.comNext earnings report:
07 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 20 Nov 2024 21:00:01 GMTDividend
Analysts recommendations
Institutional Ownership
PROF Latest News
Profound Medical Corporation (NASDAQ:PROF ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Mathieu Burtnyk - COO Conference Call Participants Benjamin Haynor - Lake Street Capital Markets John Baugh - Stifel Michael Freeman - Raymond James Scott McAuley - Paradigm Capital Operator Good day and thank you for standing by. Welcome to the Profound Medical Third Quarter 2024 Financial Results Conference Call.
Profound Medical (PROF) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.26 per share a year ago.
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024.
– Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 –
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth “Big8” Conference on September 12, 2024 in New York City.
Profound Medical Corporation (NASDAQ:PROF ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - CEO Rashed Dewan - CFO Mathieu Burtnyk - COO Conference Call Participants Rick Wise - Stifel Ben Haynor - Lake Street Capital Markets Rahul Sarugaser - Raymond James Michael Sarcone - Jefferies Scott McAuley - Paradigm Capital Brian Gagno - Gagnon Securities Operator Welcome to the Profound Medical Second Quarter 2024 Financial Results conference call. [Operator Instructions].
Profound Medical (PROF) came out with a quarterly loss of $0.28 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.35 per share a year ago.
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2024 financial results after market close on Thursday, August 8, 2024.
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 1(current)
What type of business is Profound Medical?
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
What sector is Profound Medical in?
Profound Medical is in the Healthcare sector
What industry is Profound Medical in?
Profound Medical is in the Medical Devices industry
What country is Profound Medical from?
Profound Medical is headquartered in Canada
When did Profound Medical go public?
Profound Medical initial public offering (IPO) was on 29 October 2019
What is Profound Medical website?
https://www.profoundmedical.com
Is Profound Medical in the S&P 500?
No, Profound Medical is not included in the S&P 500 index
Is Profound Medical in the NASDAQ 100?
No, Profound Medical is not included in the NASDAQ 100 index
Is Profound Medical in the Dow Jones?
No, Profound Medical is not included in the Dow Jones index
When was Profound Medical the previous earnings report?
No data
When does Profound Medical earnings report?
The next expected earnings date for Profound Medical is 07 March 2025